[go: up one dir, main page]

WO2003039436A3 - Compositions pharmaceutiques contenant de l'oxybutine - Google Patents

Compositions pharmaceutiques contenant de l'oxybutine Download PDF

Info

Publication number
WO2003039436A3
WO2003039436A3 PCT/CR2002/000007 CR0200007W WO03039436A3 WO 2003039436 A3 WO2003039436 A3 WO 2003039436A3 CR 0200007 W CR0200007 W CR 0200007W WO 03039436 A3 WO03039436 A3 WO 03039436A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
oxybutynin
dosage form
incontinence
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CR2002/000007
Other languages
English (en)
Spanish (es)
Other versions
WO2003039436A2 (fr
Inventor
Juan A Vergez
Marcelo A Ricci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osmotica Costa Rica SA
Original Assignee
Osmotica Costa Rica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25538393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003039436(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osmotica Costa Rica SA filed Critical Osmotica Costa Rica SA
Priority to AU2002363361A priority Critical patent/AU2002363361A1/en
Publication of WO2003039436A2 publication Critical patent/WO2003039436A2/fr
Publication of WO2003039436A3 publication Critical patent/WO2003039436A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique et une forme de dosage pour le traitement de l'incontinence utilisant de l'oxybutynine et une seconde substance. La seconde substance peut être tout type de substance utilisée dans le traitement de l'incontinence. Selon la voie d'administration, la forme de dosage utilisée, et la seconde substance utilisée, la forme de dosage peut comprendre indépendamment des quantités thérapeutiques ou sous-thérapeutiques d'oxybutynine et de la seconde substance. Dans des modes de réalisation particuliers, on utilise une forme de dosage assurant une libération contrôlée d'oxybutynine et de la seconde substance de façon à maintenir les niveaux thérapeutiques efficaces d'oxybutinine et/ou de la seconde substance chez un mammifère pendant une période prolongée. L'invention concerne également un dispositif osmotique comprenant un noyau bicouche. Ledit dispositif osmotique assure une libération contrôlée duale des deux substances depuis le noyau. L'invention concerne en outre une méthode de traitement de l'incontinence urinaire (par stress ou urgence) utilisant une composition pharmaceutique et une forme de dosage. Conjointement, l'oxybutynine et la seconde substance assurent un bénéfice clinique général amélioré par rapport à la même dose de tout autre agent administré tout seul.
PCT/CR2002/000007 2001-11-06 2002-11-06 Compositions pharmaceutiques contenant de l'oxybutine Ceased WO2003039436A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002363361A AU2002363361A1 (en) 2001-11-06 2002-11-06 Pharmaceutical compositions containing oxybutynin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/992,488 2001-11-06
US09/992,488 US20030185882A1 (en) 2001-11-06 2001-11-06 Pharmaceutical compositions containing oxybutynin

Publications (2)

Publication Number Publication Date
WO2003039436A2 WO2003039436A2 (fr) 2003-05-15
WO2003039436A3 true WO2003039436A3 (fr) 2004-02-26

Family

ID=25538393

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CR2002/000007 Ceased WO2003039436A2 (fr) 2001-11-06 2002-11-06 Compositions pharmaceutiques contenant de l'oxybutine
PCT/CR2002/000006 Ceased WO2003039519A2 (fr) 2001-11-06 2002-11-06 Forme de dosage a liberation controlee duale

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CR2002/000006 Ceased WO2003039519A2 (fr) 2001-11-06 2002-11-06 Forme de dosage a liberation controlee duale

Country Status (7)

Country Link
US (2) US20030185882A1 (fr)
EP (1) EP1461018A2 (fr)
AR (2) AR037255A1 (fr)
AU (2) AU2002363360A1 (fr)
BR (1) BR0213948A (fr)
UY (2) UY27533A1 (fr)
WO (2) WO2003039436A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
EP2085072A1 (fr) * 2002-03-26 2009-08-05 Teva Pharmaceutical Industries Ltd. Microparticules de médicament
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
US20050175697A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms of topiramate
JP2005536568A (ja) * 2002-07-29 2005-12-02 アルザ・コーポレーシヨン トピラメートの調節分配用の調剤および投薬形態
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20050271691A1 (en) * 2003-02-21 2005-12-08 Cardio Combos Llc Prepackaged aqueous pharmaceutical formulations
MXPA06001548A (es) * 2003-08-06 2006-09-04 Johnson & Johnson Suministro uniforme de topiramato durante un periodo prolongado con formulaciones de dispersion.
EP2210605B1 (fr) * 2003-11-04 2017-03-01 TCD Royalty Sub, LLC Forme dosifiée quotidienne de trospium
EP1680100A4 (fr) 2003-11-04 2012-08-08 Supernus Pharmaceuticals Inc Composes d'ammonium quaternaire contenant des activateurs de la biodisponibilite
WO2005065646A2 (fr) * 2003-12-29 2005-07-21 Alza Corporation, Inc., Compositions medicamenteuses et formes pharmaceutiques
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
CA2556216A1 (fr) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Methodes et compositions de traitement de troubles psychiatriques
WO2005105036A1 (fr) * 2004-04-28 2005-11-10 Natco Pharma Limited Matrice muco-adhesive a liberation controlee contenant de la tolterodine, et procede d'elaboration
EP1629834A1 (fr) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Composition pharmaceutique de tolterodine avec liberation soutenue
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
WO2006080029A1 (fr) 2005-01-27 2006-08-03 Alembic Limited Formulation de lévétiracétam à libération prolongée
EP1896002A4 (fr) * 2005-06-27 2009-11-25 Biovail Lab Int Srl Formulations a liberation modifiee d'un sel de bupropion
EP2032124A1 (fr) * 2006-06-27 2009-03-11 Biovail Laboratories International Srl Système de délivrance osmotique multiparticulaire
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
EP2175843B1 (fr) * 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Compositions à libération prolongée comprenant de la toltérodine
WO2009052353A2 (fr) * 2007-10-17 2009-04-23 Dr. Reddy's Laboratories Ltd. Formulations pharmaceutiques de trospium
WO2010089259A2 (fr) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Composition à libération prolongée contenant de la quétiapine
WO2011161504A1 (fr) * 2010-06-23 2011-12-29 Micro Labs Limited Formulations à libération prolongée contenant de la darifénacine ou des sels pharmaceutiquement acceptables de celle-ci
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法
CN103156804A (zh) * 2011-12-13 2013-06-19 重庆医药工业研究院有限责任公司 一种奥昔布宁透皮凝胶及其制备方法
DK2851075T3 (da) * 2012-05-14 2022-01-31 Shionogi & Co Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
CN103127023B (zh) * 2013-03-01 2014-08-27 河北天成药业股份有限公司 一种盐酸度洛西汀肠溶片及其制备方法
JP6878417B2 (ja) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド 剤形およびそれらの使用
GB201708224D0 (en) * 2017-05-23 2017-07-05 Juniper Pharmaceuticals Uk Ltd Device
NZ766673A (en) * 2018-01-30 2025-08-29 Apnimed Inc Delaware Methods and compositions for treating sleep apnea
EP4146621A1 (fr) 2020-05-05 2023-03-15 Apnimed, Inc. (Delaware) Formes polymorphes de chlorhydrate de (r)-oxybutynine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4455143A (en) * 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
ES2008580A6 (es) * 1987-09-03 1989-07-16 Alza Corp Forma de dosificacion para la liberacion rapida y lenta de agente beneficioso.
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
ES2141044A1 (es) * 1997-02-26 2000-03-01 Alza Corp Terapia con oxibutinina.
ES2150663T3 (es) * 1995-01-31 2000-12-01 Sepracor Inc Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.
EP1123705A1 (fr) * 2000-02-09 2001-08-16 Pfizer Products Inc. Combinaisons pharmaceutiques pour le traitement de troubles fonctionnels de l' uretère inférieur

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4309996A (en) * 1980-04-28 1982-01-12 Alza Corporation System with microporous releasing diffusor
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4552880A (en) * 1983-02-15 1985-11-12 Merrell Dow Pharmaceuticals Inc. Aroylimidazolones
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US4627971A (en) * 1985-04-22 1986-12-09 Alza Corporation Osmotic device with self-sealing passageway
US4661583A (en) * 1985-06-24 1987-04-28 Ashland Oil, Inc. Reaction of bicyclic amide acetal with imide
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US4867969A (en) * 1986-02-07 1989-09-19 Alza Corporation Hydrogel formulation for administering non-steroidal drugs
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US4960416A (en) * 1986-04-30 1990-10-02 Alza Corporation Dosage form with improved delivery capability
US4863456A (en) * 1986-04-30 1989-09-05 Alza Corporation Dosage form with improved delivery capability
US5082663A (en) * 1986-08-20 1992-01-21 Teikoku Seiyaky Co., Ltd. External adhesive preparation containing steroids
US4765957A (en) * 1986-12-29 1988-08-23 Carondelet Foundry Company Alloy resistant to seawater and other corrosive fluids
DE3716260C1 (de) * 1987-05-15 1988-07-28 Dyckerhoff & Widmann Ag Verfahren zur Justierung und Befestigung von Funktionsflaechen eines Fahrwegs einer elektromagnetischen Schnellbahn und Vorrichtung zur Durchfuehrung des Verfahrens
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4904474A (en) 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5006348A (en) * 1990-05-04 1991-04-09 Kraft General Foods, Inc. Method for manufacture of swiss cheese
DE59001019D1 (de) * 1990-06-13 1993-04-15 Manfred Oelsner Verfahren zur herstellung von pektin- und zuckerhaltigen zubereitungen, wie konfituere, marmelade od.gdl.
US5976571A (en) * 1991-01-31 1999-11-02 Port Systems, L.L.C. Method for making a multi-stage drug delivery system
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
JP2646170B2 (ja) 1992-06-24 1997-08-25 日本ヘキスト・マリオン・ルセル株式会社 徐放性塩酸オキシブチニン製剤
US5643155A (en) * 1993-11-02 1997-07-01 Kallassy; Charles Aquatic exercise device
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
WO1996012477A1 (fr) 1994-10-21 1996-05-02 Leiras Oy Systeme d'administration orale a liberation lente contenant de l'oxybutynine
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO1997016814A1 (fr) 1995-11-03 1997-05-09 Sierra Semiconductor Corporation Filtre video yuv place a l'extremite arriere
JP2665658B2 (ja) 1995-12-18 1997-10-22 住友特殊金属株式会社 希土類・鉄・コバルト・ボロン系正方晶化合物
ES2168610T3 (es) * 1996-03-12 2002-06-16 Alza Corp Composicion y forma galenica que contiene un antagonista opioide.
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5866184A (en) * 1997-03-12 1999-02-02 World Class Packaging Systems, Inc. Method of packaging a food product in a ventable package
CN1158071C (zh) * 1997-05-30 2004-07-21 渗透有限公司 多层渗透装置
CN1239152C (zh) 1998-08-27 2006-02-01 法玛西雅和厄普约翰公司 控释给药托耳替罗地的治疗制剂
AU1256399A (en) 1998-10-07 2000-04-26 Alza Corporation Controlled release dosage from comprising oxybutynin
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
PT1257277E (pt) * 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4455143A (en) * 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
ES2008580A6 (es) * 1987-09-03 1989-07-16 Alza Corp Forma de dosificacion para la liberacion rapida y lenta de agente beneficioso.
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
ES2150663T3 (es) * 1995-01-31 2000-12-01 Sepracor Inc Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.
ES2141044A1 (es) * 1997-02-26 2000-03-01 Alza Corp Terapia con oxibutinina.
EP1123705A1 (fr) * 2000-02-09 2001-08-16 Pfizer Products Inc. Combinaisons pharmaceutiques pour le traitement de troubles fonctionnels de l' uretère inférieur

Also Published As

Publication number Publication date
US20030185882A1 (en) 2003-10-02
AU2002363360A1 (en) 2003-05-19
AU2002363361A1 (en) 2003-05-19
US20060177510A1 (en) 2006-08-10
WO2003039436A2 (fr) 2003-05-15
AR037255A1 (es) 2004-11-03
BR0213948A (pt) 2004-08-31
WO2003039519A2 (fr) 2003-05-15
EP1461018A2 (fr) 2004-09-29
WO2003039519A3 (fr) 2004-03-25
UY27532A1 (es) 2003-05-30
AR037256A1 (es) 2004-11-03
UY27533A1 (es) 2003-05-30
US8241667B2 (en) 2012-08-14

Similar Documents

Publication Publication Date Title
WO2003039436A3 (fr) Compositions pharmaceutiques contenant de l'oxybutine
Muindi et al. Pharmacokinetics of high‐dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
BR0108730A (pt) Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
EP1275381A4 (fr) Compositions solides enrobees a liberation decalee dans le temps
AU3805195A (en) Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast
HU212422B (en) Process for preparing pharmaceutical compositions containing dipyridamole for the treatment of proliferative diseases
BR0013540A (pt) Formulações farmacêuticas e seu uso na prevenção de acidente vascular cerebral, diabetes e/ou falha de coração congestiva
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
WO2004045578A3 (fr) Composes organiques
BRPI0117180B8 (pt) composição farmacêutica em uma forma de unidade sólida de dosagem para a administração oral a um ser humano ou animal inferior
SG146638A1 (en) Pharmaceutical delivery system
WO2001030802A3 (fr) Traitements therapeutiques pour des deficiences en cellules sanguines
WO2005007072A3 (fr) Methodes et compositions pharmaceutiques pour cicatriser des lesions
CA2387486A1 (fr) Utilisation de dipyridamole ou de mopidamol dans la fabrication d'un medicament de traitement et de prevention de troubles de la microcirculation lies a la fibrine
WO2001068125A3 (fr) Methodes et compositions de traitement et de prevention de la dyserection
WO2005044186A3 (fr) Formulations pharmaceutiques destinees a etre inhalees utilisant des agents dessechants et methodes d'administration desdites formulations pharmaceutiques
WO2002034267A8 (fr) Combinaison d'un systeme therapeutique transdermal et d'une preparation orale et/ou parenterale contenant des agonistes dopaminergiques pour traiter des maladies en relation avec la dopamine
CA2433833A1 (fr) Utilisation de flumazenil dans l'elaboration d'un medicament visant a traiter la dependence a l'alcool
WO2005094899A8 (fr) Traitement de cancers par un antisens anti-clusterine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP